JP Patent

JP2017508817A — 肝内胆汁うっ滞症の治療

Assigned to CymaBay Therapeutics Inc · Expires 2017-03-30 · 9y expired

What this patent protects

本発明は、ＭＢＸ−８０２５またはＭＢＸ−８０２５塩を用いた療法による肝内胆汁うっ滞症の治療を提供する。

USPTO Abstract

本発明は、ＭＢＸ−８０２５またはＭＢＸ−８０２５塩を用いた療法による肝内胆汁うっ滞症の治療を提供する。

Drugs covered by this patent

seladelpar-lysine (SELADELPAR LYSINE)

Patent Metadata

Patent number: JP2017508817A
Jurisdiction: JP
Classification: —
Expires: 2017-03-30
Drug substance claim: No
Drug product claim: No
Assignee: CymaBay Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.